戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 he inhibition of secretary phospholipase A2 (sPLA2).
2 n/vesicle aggregation, as observed for hGIIA sPLA2.
3 xpression of group V sPLA2 but IIA not group sPLA2.
4 A2 and nonpancreatic human group IIA (hGIIA) sPLA2.
5 cles comparable to that of the human group V sPLA2.
6  the number of cells staining positively for sPLA2.
7 erably larger in hGX than in human group IIA sPLA2.
8 ade PIN showed positive immunoreactivity for sPLA2.
9 injury (MOF sPLA2, 2.4 +/- 0.97, vs. non-MOF sPLA2, 0.86 +/- 0.16 active units (AU); p < .05) and con
10 A2 activity beginning 36 hrs postinjury (MOF sPLA2, 2.4 +/- 0.97, vs. non-MOF sPLA2, 0.86 +/- 0.16 ac
11                       We show that group IIA sPLA2, a known genetic modifier of mouse intestinal tumo
12 enables further studies of the mechanisms of sPLA2 action influencing the development and tumorigenes
13 vity, the protease(s) responsible for pro-GX sPLA2 activation have not been identified.
14 as no association of rs525380C>A with plasma sPLA2 activity (difference in geometric mean of sPLA2 ac
15   We tested the association of this SNP with sPLA2 activity and CHD events in 4 prospective and 14 ca
16 s show a strong association between elevated sPLA2 activity and CHD, no assay to measure sPLA2-V leve
17 he contribution of sPLA2-X to the measure of sPLA2 activity and coronary heart disease (CHD) risk tra
18 nate mucosal immunity by suppressing luminal sPLA2 activity and MUC2 density compared with chow.
19  non-MOF patients, MOF patients had elevated sPLA2 activity beginning 36 hrs postinjury (MOF sPLA2, 2
20 able to distinguish differences in levels of sPLA2 activity between neoplasia-resistant strains, whic
21 nal ensemble averaging methods used to probe sPLA2 activity do not allow one to obtain such informati
22                                              sPLA2 activity encompasses several sPLA2 isoenzymes, inc
23 ped a sensitive assay to directly quantitate sPLA2 activity in the murine intestinal tract utilizing
24  suppressed FLAG-pro-GX sPLA2 processing and sPLA2 activity in Y1 cells, and it significantly attenua
25                   We conclude that increased sPLA2 activity is associated with the development of pos
26  tissue was harvested for analysis of tissue sPLA2 activity or immediate use in an ex-vivo intestinal
27 are not significantly associated with plasma sPLA2 activity or with CHD risk.
28 A2 activity (difference in geometric mean of sPLA2 activity per rs525380 A-allele 0.4% (95% confidenc
29                                              sPLA2 activity was sequentially measured and correlated
30 C-Norfolk subjects in the highest tertile of sPLA2 activity were older and had higher inflammatory ma
31  variant, were significantly associated with sPLA2 activity, intermediate CHD risk traits, or CHD ris
32 h fluid (SIWF) was collected for analysis of sPLA2 activity, MUC2 density, and luminal levels of IL-4
33 ompared with those in the lowest tertile for sPLA2 activity.
34 dies report that secretory phospholipase A2 (sPLA2) activity is a marker for coronary heart disease (
35 owever, eosinophils also have secreted PLA2 (sPLA2) activity that has not been fully defined.
36 ine if intestinal secreted phospholipase A2 (sPLA2) activity was also attenuated in susceptible strai
37     Likewise, SC secretory phospholipase A2 (sPLA2) activity, measured with a fluorometric assay, is
38 ted that group V secretory phospholipase A2 (sPLA2) amplifies the action of cytosolic phospholipase A
39                                         When sPLA2 and cPLA2alpha are both present, the effect of H2O
40      Interleukin-4 (IL-4) and IL-13 regulate sPLA2 and MUC2 production through the IL-13 receptor.
41 L-4 and IL-13 release and PN reduces luminal sPLA2 and MUC2, we hypothesized that adding IL-25 to PN
42 erses this dysfunction and increases luminal sPLA2 and MUC2.
43 cation by two endogenous mechanisms, namely, sPLA2 and NHE1, which are known to be important for acid
44 : Agkistrodon piscivorus piscivorus (AppD49) sPLA2 and nonpancreatic human group IIA (hGIIA) sPLA2.
45 nd PGE2 , plasma secretory phospholipase A2 (sPLA2 ), and 11beta prostaglandin F2alpha (11betaPGF2alp
46 crobial molecule secretory phospholipase A2 (sPLA2) and the goblet cell glycoprotein mucin2 (MUC2).
47 ted with the human Group V secreted PLA2 (GV sPLA2) and the human Group VIA calcium-independent PLA2
48 de compound had appreciable inhibition of GV sPLA2, and none of the potent GIVA cPLA2 inhibitors inhi
49 the putative membrane binding surface of the sPLA2 are modestly more important for bactericidal activ
50 the first 5 d after birth, and inhibition of sPLA2 between days 0 to 1 and days 5 to 6 delays postnat
51         These results suggest that preferred sPLA2 binding conformation of the natural product is sim
52 ase packing of DAPC and DMPE interferes with sPLA2 binding, irrespective of the phospholipid headgrou
53 restored by adenoviral expression of group V sPLA2 but IIA not group sPLA2.
54                    Group IIa secretory PLA2 (sPLA2) can generate arachidonate from cellular phospholi
55               The inhibition is dependent on sPLA2 catalytic activity and primarily due to hydrolysis
56 he inflammatory-type human group IIA (hGIIA) sPLA2 circulates at high levels in the serum of malaria
57 f the products tested had elevated levels of sPLA2 compared with fresh plasma from healthy adult volu
58 g of sPLA2 was monitored using a fluorescein-sPLA2 conjugate.
59          These data demonstrate that group V sPLA2 contributes to the innate immune response both thr
60                      Using the human group X sPLA2 crystal structure, we prepared a highly potent and
61 as measured in vivo in wild-type (WT) and GX sPLA2-deficient (GX KO) mice and ex vivo using pancreati
62 Y1 cells, and it significantly attenuated GX sPLA2-dependent inhibition of steroidogenic acute regula
63 omposition, all GUVs were reduced in size as sPLA2-dependent lipid hydrolysis proceeded.
64 of lateral packing of the lipids in C. atrox sPLA2 enzymatic hydrolysis of a membrane surface.
65  circulating sPLA2-IIA mass (38% to 44%) and sPLA2 enzyme activity (3% to 23%) per C allele.
66 analysis failed to show associations between sPLA2 enzyme activity and MVE.
67 gher circulating levels of sPLA2-IIA mass or sPLA2 enzyme activity have been associated with increase
68 ual members of the large family of mammalian sPLA2 enzymes.
69                  Secretory phospholipase A2 (sPLA2) enzymes are considered to play a role in atherosc
70 molecular weight secretory phospholipase A2 (sPLA2) enzymes in eicosanoid generation have relied on d
71 e indicates that secretory phospholipase A2 (sPLA2) enzymes promote atherogenic processes.
72 is study, using a FLAG epitope-tagged pro-GX sPLA2 expression construct (FLAG-pro-GX sPLA2), we deter
73                    We examined the group IIa sPLA2 expression in benign prostatic tissues, prostatic
74                       We demonstrate that gV-sPLA2 expression in M is sufficient for the development
75 IN), and adenocarcinoma to determine whether sPLA2 expression is altered in the carcinogenesis of hum
76 onsistent with the contention that group IIA sPLA2 expression is elevated in neoplastic prostatic tis
77                  Secretory phospholipase A2 (sPLA2) generates bioactive phospholipid products implica
78 ence of cPLA2 and secreted phospholipase A2 (sPLA2) Group IIA, Group V, and Group X on IL-8 and COX-2
79 ve previously showed the presence of Group V sPLA2 (GV sPLA2) in human and mouse atherosclerotic lesi
80 man group X (hGX) secreted phospholipase A2 (sPLA2) has been solved to a resolution of 1.97 A.
81                                              sPLA2 hydrolyzes the liquid domains in the binary lipid
82       Group X secretory phospholipase A2 (GX sPLA2) hydrolyzes mammalian cell membranes, liberating f
83                                              sPLA2 IB enhanced podocyte arachidonic acid (AA) content
84                     These data indicate that sPLA2 IB has the potential to induce human podocyte apop
85          However, the roles of the PLA2R and sPLA2 IB in the pathogenesis of glomerular diseases are
86                After binding with the PLA2R, sPLA2 IB induced podocyte apoptosis in a time- and conce
87 neys of patients with higher PLA2R and serum sPLA2 IB levels.
88         Group IB secretory phospholipase A2 (sPLA2 IB), which is one of the ligands of the PLA2R, is
89                                              sPLA2 IB-induced podocyte PLA2R upregulation was not onl
90                                          The sPLA2 IB-PLA2R interaction stimulated podocyte apoptosis
91  significantly attenuated infarction volume, sPLA2 IIA protein expression, PLA2 activity and signific
92 uggests that cytokine induction up-regulates sPLA2 IIA protein expression, resulting in altered lipid
93 egulation of secretory phospholipase A2 IIA (sPLA2 IIA) mRNA and protein expression, increased PLA2 a
94 gate the role of secretory phospholipase A2 (sPLA2)-IIA in cardiovascular disease.
95 tly increased PLA2 activity, secretory PLA2 (sPLA2)-IIA mRNA and protein levels, PtdCho-PLC activity,
96         We identified amino acid residues in sPLA2-IIA (Arg-74 and Arg-100) that are critical for int
97 ggest that both secretory PLA2 (sPLA2)-V and sPLA2-IIA (encoded, respectively, by the neighbouring PL
98 n a previous study, a selective inhibitor of sPLA2-IIA (LY315920NA/S-5920) was well tolerated and app
99 s of intestinal tissues were consistent with sPLA2-IIA activity levels.
100 own by sequencing to carry variant wild-type sPLA2-IIA alleles.
101                                              sPLA2-IIA also bound to alpha4beta1.
102 in vitro CN and CNJ culturing confirmed that sPLA2-IIa amplifies ocular surface inflammation in CNJ b
103 found in neutrophils only in the presence of sPLA2-IIA and 12-LO in an in vivo model of autoimmune in
104 mice, we show that the coordinated action of sPLA2-IIA and 12-LO promotes inflammatory arthritis.
105 o determine whether the relationship between sPLA2-IIA and coronary heart disease is causal.
106           Treated mice exhibited upregulated sPLA2-IIa and cytokine gene transcription.
107 3 and alpha4beta1 may serve as receptors for sPLA2-IIA and mediate pro-inflammatory action of sPLA2-I
108 er, the M-type receptor is species-specific: sPLA2-IIA binds to the M-type receptor in rodents and ra
109                    Here we demonstrated that sPLA2-IIA bound to integrin alphavbeta3 at a high affini
110  isolates are highly sensitive to killing by sPLA2-IIA but not by human antimicrobial peptides.
111 sive GBS disease contain increased levels of sPLA2-IIA compared with normal sera from healthy individ
112                               We showed that sPLA2-IIA competed with VCAM-1 for binding to alpha4beta
113                S. aureus adsA strain induced sPLA2-IIA expression by alveolar macrophages after phago
114 adenosine production (adsA strain) increased sPLA2-IIA expression in guinea pig airways and was clear
115              Ocular surface inflammation and sPLA2-IIa expression were examined by immune-staining an
116 veolar macrophages, leading to inhibition of sPLA2-IIA expression.
117 sine-mediated inhibition of phagocytosis and sPLA2-IIA expression.
118                                              sPLA2-IIa function was confirmed via in vitro CN and CNJ
119         Consistent with predictions from the sPLA2-IIA gene sequence in inbred strains, we detected l
120 Continuous 7-day infusion of an inhibitor of sPLA2-IIA had no beneficial effect on 28-day all-cause m
121        Moreover, treated mice showed heavier sPLA2-IIa immune staining than the controls in the CNJ e
122 (DE) model was used to elucidate the role of sPLA2-IIa in ocular surface inflammation.
123           This is the first report regarding sPLA2-IIa in the regulation of ocular surface inflammati
124 nd the catalytically inactive H47Q mutant of sPLA2-IIA induced cell proliferation and ERK1/2 activati
125       Independent of its catalytic activity, sPLA2-IIA induces pro-inflammatory signals in a receptor
126       Furthermore, CNJ cultures treated with sPLA2-IIa inhibitor showed significantly reduced sPLA2-I
127  induced by sPLA2-IIa with various amount of sPLA2-IIa inhibitor, S-3319.
128 atory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a novel therapeutic target.
129                                              sPLA2-IIa is a biomarker for many inflammatory diseases
130                                      Because sPLA2-IIA is induced during inflammation, and 12-LO expr
131 s11573156, a variant in PLA2G2A encoding the sPLA2-IIA isoenzyme, as an instrumental variable.
132  previously associated with higher and lower sPLA2-IIA levels respectively.
133 6 C allele associated with lower circulating sPLA2-IIA mass (38% to 44%) and sPLA2 enzyme activity (3
134 ) levels yet lower oxLDL/LDL (P = 0.006) and sPLA2-IIA mass (P = 0.04), probably reflecting LD with P
135                                     Reducing sPLA2-IIA mass is unlikely to be a useful therapeutic go
136                 Higher circulating levels of sPLA2-IIA mass or sPLA2 enzyme activity have been associ
137 able analysis for MVE for a 1-log unit lower sPLA2-IIA mass was 1.04 (95% CI: 0.96 to 1.13), and diff
138 ypes of PLA2G2A are strongly associated with sPLA2-IIA mass, but not lipid levels.
139 t is entirely due to sPLA2-IIA, showing that sPLA2-IIA might represent an important component of humo
140 ment significantly attenuated PLA2 activity, sPLA2-IIA mRNA and protein levels, and PtdCho-PLC activi
141 enzyme activity in inbred strains containing sPLA2-IIA mutations; these strains were also associated
142                              Elevated plasma sPLA2-IIA predicts coronary heart disease (CHD) risk, bu
143 vide experimental and clinical evidence that sPLA2-IIA protects humans against GBS infections.
144                                         Thus sPLA2-IIA receptors in human have not been established.
145  individuals, indicating that GBS induces an sPLA2-IIA response in blood during human infection.
146 d for prostaglandin E2 production induced by sPLA2-IIa with various amount of sPLA2-IIa inhibitor, S-
147  hydrolysis of the mitochondrial membrane by sPLA2-IIA yields inflammatory mediators (ie, lysophospho
148        Secretory phospholipase A2 group IIA (sPLA2-IIA) has been identified as a biomarker of atheros
149     The type IIA secretory phospholipase A2 (sPLA2-IIA) is a host protein endowed with antibacterial
150        Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an important role in the pathogenesis o
151 f human group IIA secreted phospholipase A2 (sPLA2-IIA), a bactericidal enzyme induced during acute i
152  substrate of secreted phospholipase A2 IIA (sPLA2-IIA), a phospholipase otherwise specific for bacte
153 d activity of secreted phospholipase A2 IIA (sPLA2-IIA), present in inflammatory fluids, and platelet
154        Group IIA secretory phospholipase A2 (sPLA2-IIA), released during inflammation, is increased i
155                                       IFA of sPLA2-IIa, -V, and -X in DE CNJ confirmed the upregulati
156        Immunofluorescence assay (IFA) of the sPLA2-IIa, -V, and -X isoforms were used to confirm qRT(
157 ought to represent the composite activity of sPLA2-IIA, -V, and -X.
158 2-IIA and mediate pro-inflammatory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a
159  phase response in which serum amyloid A and sPLA2-IIa, present at sites of inflammation and tissue d
160 s Ptd-Cho levels by differentially affecting sPLA2-IIA, PtdCho-PLC, and CCTalpha after transient foca
161 t the bactericidal effect is entirely due to sPLA2-IIA, showing that sPLA2-IIA might represent an imp
162     Using transgenic mice that express human sPLA2-IIA, we demonstrate that this enzyme is crucial fo
163 2-IIa inhibitor showed significantly reduced sPLA2-IIa-induced inflammation.
164  but catalytic activity is not required, for sPLA2-IIA-induced proliferative signaling.
165 ggest that, in the airway, S. aureus escapes sPLA2-IIA-mediated killing through adenosine-mediated in
166            However, the role of adenosine in sPLA2-IIA-mediated S. aureus killing by host is still un
167 s) expressed cPLA2-IVA, cPLA2-IVB, iPLA2-VI, sPLA2-IIE, and sPLA2-XIIA.
168                             The intensity of sPLA2 immunoreactivity was also different among benign p
169 r studies identified a unique function of gV-sPLA2 in activation of M and in their capacity to recrui
170  relative concentration variations of active sPLA2 in CSF and the specific enzymatic activity can be
171  Adoptive transfer studies suggested that gV-sPLA2 in dendritic cells was necessary for sensitization
172 provide clear evidence of a role for group V sPLA2 in regulating eicosanoid generation in response to
173                      Overexpression of human sPLA2 in transgenic mice reduces both HDL cholesterol an
174 sly showed the presence of Group V sPLA2 (GV sPLA2) in human and mouse atherosclerotic lesions, its h
175  of detection (LOD) of human secretory PLA2 (sPLA2) in up to 1000-fold-diluted cerebrospinal fluid (C
176                                          The sPLA2 inhibition with varespladib may be harmful and is
177      A recent phase III clinical trial of an sPLA2 inhibitor (varespladib) was stopped prematurely fo
178                                          The sPLA2 inhibitor varespladib has favorable effects on lip
179 ved from LY315920, a well-known indole-based sPLA2 inhibitor.
180 chemically unrelated secretory phospholipase sPLA2 inhibitors, bromphenacylbromide and 1-hexadecyl-3-
181 on is replaced with a Z-olefin or an alkyne, sPLA2 inhibitory activity suffered relative to the natur
182 findings provide strong evidence that pro-GX sPLA2 is a substrate for furin and PCSK6 proteolytic pro
183  cells in the small intestine, while group X sPLA2 is expressed by Paneth/goblet-like cells in the co
184         In this study, we determined that GX sPLA2 is expressed in insulin-producing cells of mouse p
185        In this study, we demonstrate that gV-sPLA2 is inducibly expressed in mouse and human macropha
186                       We report that group V sPLA2 is present in the Golgi apparatus and recycling en
187                                           GX sPLA2 is produced as a pro-enzyme (pro-GX sPLA2) that co
188 san by mouse peritoneal macrophages, group V sPLA2 is recruited to the phagosome.
189  that: 1) the overall positive charge of the sPLA2 is the dominant factor in dictating bactericidal p
190       Group IIA secreted phospholipase A(2) (sPLA2) is known to display potent Gram-positive bacteric
191           sPLA2 activity encompasses several sPLA2 isoenzymes, including sPLA2-V.
192 sent in all tissues of both strains, whereas sPLA2 isoforms (pla2g1b, 2e, and 3) were absent.
193                                              sPLA2 isoforms (pla2g2a, 2d, 2f, and 10) showed tissue-
194                     qRT(2)-PCR revealed that sPLA2 isoforms (pla2g5, 12a, and 12b), cPLA2 isoform (pl
195                                              sPLA2 isoforms exhibit differential expression patterns
196    These findings suggest that at least some sPLA2 isoforms must have significant roles in ocular sur
197                    Gene expression of select sPLA2 isoforms was quantified via real-time reverse-tran
198 whereas IL-25 significantly increased tissue sPLA2 levels compared with PN alone.
199 have identified a secreted phospholipase A2 (sPLA2)-like protein, BomoTx, from the Brazilian lancehea
200 ession levels of secretory phospholipase A2 (sPLA2), lysophospholipid acyltransferase (LPEAT), lysoph
201 support the hypothesis that dysregulation of sPLA2 may play a role in prostatic carcinogenesis.
202 IS was lower in MIN6 cells overexpressing GX sPLA2 (MIN6-GX) compared with control (MIN6-C) cells.
203 otein (LDL) particles, and the ability of GV sPLA2-modified LDL (GV-LDL) to induce macrophage foam ce
204               We previously reported that GX sPLA2 negatively regulates adrenal glucocorticoid produc
205 y 50% in peritoneal macrophages from group V sPLA2-null mice compared with macrophages from wild-type
206 otrienes were markedly attenuated in group V sPLA2-null mice compared with wild-type controls.
207 hermore, peritoneal macrophages from group V sPLA2-null mice demonstrated a >50% attenuation in phago
208                             The effect of GX sPLA2 on GSIS was abolished when cells were treated with
209 ect of deletion of the gene encoding group V sPLA2 on phagocytosis of zymosan.
210 nt GIVA cPLA2 inhibitors inhibited either GV sPLA2 or GVIA iPLA2.
211 IN6 pancreatic beta cells with or without GX sPLA2 overexpression or exogenous addition.
212 he addition of IL-25 to PN increased luminal sPLA2 (P < 0.0001) and MUC2 (P < 0.02) compared with PN.
213                           PN reduced luminal sPLA2 (P < 0.0001) and MUC2 (P <0.002) compared with cho
214                          We conclude that GX sPLA2 plays a previously unrecognized role in negatively
215       Group X secretory phospholipase A2 (GX sPLA2) potently hydrolyzes membrane phospholipids to rel
216 are formed by internalization of the Group V sPLA2 previously associated with the outer cellular surf
217 cotropic hormone (ACTH) enhanced FLAG-pro-GX sPLA2 processing and phospholipase activity secreted by
218  ketone significantly suppressed FLAG-pro-GX sPLA2 processing and sPLA2 activity in Y1 cells, and it
219  PCs almost completely abolished FLAG-pro-GX sPLA2 processing in Y1 cells.
220 293 cells significantly enhanced FLAG-pro-GX sPLA2 processing, whereas siRNA-mediated knockdown of bo
221                  Secretory phospholipase A2 (sPLA2) produces many inflammatory lipid mediators, and l
222 matory response, secretory phospholipase A2 (sPLA2) reaches its maximum levels in plasma, where it is
223                                    Different sPLA2's utilize different combinations of electrostatic
224                  Secreted phospholipases A2 (sPLA2's) are enzymes that hydrolyze glycerophospholipids
225 ane association of two highly basic group II sPLA2's: Agkistrodon piscivorus piscivorus (AppD49) sPLA
226 cking group V secretory phospholipase A2 (gV-sPLA2) showed reduced eosinophilic pulmonary inflammatio
227 otein fold is similar to previously reported sPLA2 structures.
228 GX sPLA2 is produced as a pro-enzyme (pro-GX sPLA2) that contains an N-terminal 11-amino acid propept
229  for patient resuscitation was the source of sPLA2, the sPLA2 was measured in packed red blood cells,
230 oes not resemble that of the human group IIA sPLA2; the former is highly neutral, whereas the latter
231 n of the ability of the acidic human group X sPLA2 to kill Gram-positive bacteria.
232 er furin or PCSK6 enhanced the ability of GX sPLA2 to suppress liver X receptor reporter activity.
233 y was to characterize the plasma activity of sPLA2 type IIa in severely injured patients and to deter
234  a switch to a sequential induction of first sPLA2 (types IIa and V) that mediates the release of PAF
235 an studies suggest that both secretory PLA2 (sPLA2)-V and sPLA2-IIA (encoded, respectively, by the ne
236 causally related, because cells deficient in sPLA2-V exhibited decreased phagocytosis, and cells over
237                  In parallel with increasing sPLA2-V expression levels, IL-4-treated macrophages exhi
238                    Here, we use tSNPs of the sPLA2-V gene to investigate the association of PLA2G5 wi
239  evidence does not support a causal role for sPLA2-V in CHD.
240  investigate the hypothesized causal role of sPLA2-V in coronary heart disease (CHD) pathogenesis.
241 rt disease (CHD) risk, but no mass assay for sPLA2-V is available.
242          Collectively, our results show that sPLA2-V is required for efficient phagocytosis by IL-4-t
243 ls exists, and the only evidence linking the sPLA2-V isoform to atherosclerosis progression comes fro
244  sPLA2 activity and CHD, no assay to measure sPLA2-V levels exists, and the only evidence linking the
245 phism for PLA2G5 expression, a surrogate for sPLA2-V levels) and CHD events.
246 absence of an assay that directly quantifies sPLA2-V levels, we used PLA2G5 mRNA levels in a novel, m
247 PLA2G5 mRNA expression levels as a proxy for sPLA2-V levels.
248 on of the secreted group V phospholipase A2 (sPLA2-V), both at the mRNA and protein levels.
249                             By supplementing sPLA2-V-deficient cells with LPE, phagocytosis of zymosa
250  human macrophages and provide evidence that sPLA2-V-derived LPE is involved in the process.
251 at ethanolamine lysophospholipid (LPE) is an sPLA2-V-derived product that may be involved in regulati
252  levels of LPE are selectively maintained by sPLA2-V.
253 ompasses several sPLA2 isoenzymes, including sPLA2-V.
254 t resuscitation was the source of sPLA2, the sPLA2 was measured in packed red blood cells, platelet c
255                               The binding of sPLA2 was monitored using a fluorescein-sPLA2 conjugate.
256                                          The sPLA2 was observed to associate with the entire surface
257             The number of cells staining for sPLA2 was significantly less in benign epithelium (4%) a
258 o-GX sPLA2 expression construct (FLAG-pro-GX sPLA2), we determined that adrenocorticotropic hormone (
259    To further understand the role of group V sPLA2, we studied its localization in resting mouse peri
260             To elucidate the role of group V sPLA2, we used targeted gene disruption to generate mice
261                             Tissue levels of sPLA2 were significantly decreased with PN compared with
262 e immunohistochemical staining for group IIA sPLA2, whereas 63 of 69 total cases (91%) of high-grade
263 cytes is group X secretory phospholipase A2 (sPLA2), which liberates large amounts of AA and the lyso
264 of Crotalus atrox-secreted phospholipase A2 (sPLA2) with giant unilamellar vesicles (GUVs) composed o
265                              An inhibitor of sPLA2-X (ROC-0929) that does not inhibit other mammalian
266 ain lysophospholipid released in response to sPLA2-X activity, stimulates melanocyte dendricity.
267 al a relationship between epithelial-derived sPLA2-X and indirect AHR in asthma and that sPLA2-X serv
268 e treated human melanocytes with recombinant sPLA2-X and show that low levels of sPLA2-X stimulate bo
269                     A rabbit polyclonal anti-sPLA2-X antibody identified sPLA2-X by Western blot.
270                 We found that the effects of sPLA2-X are mediated predominantly by LPC, not AA, and w
271  polyclonal anti-sPLA2-X antibody identified sPLA2-X by Western blot.
272                            The regulation of sPLA2-X gene (PLA2G10) expression was examined in primar
273            Eosinophils express the mammalian sPLA2-X gene (PLA2G10).
274 tion, our data suggest an important role for sPLA2-X in cutaneous pigmentation through the release of
275                   The function of epithelial sPLA2-X in eicosanoid formation was examined using PLA2
276                         We sought to examine sPLA2-X in the airway epithelium and airway wall of pati
277                            The expression of sPLA2-X increases during in vitro epithelial differentia
278                                    Selective sPLA2-X inhibition attenuated the fMLP-mediated release
279                                          The sPLA2-X inhibitor reduced the phosphorylation of p38 and
280                  We further demonstrate that sPLA2-X is activated before secretion from the cell duri
281  during cellular activation, indicating that sPLA2-X is involved in activating the MAPK cascade leadi
282 ents with asthma and that epithelial-derived sPLA2-X may be increased in association with indirect AH
283               Therapies targeting epithelial sPLA2-X may be useful in asthma.
284                Treatment of melanocytes with sPLA2-X or LPC induced phosphorylation of the zeta isofo
285               These results demonstrate that sPLA2-X plays a significant role in the formation of Cys
286                                              sPLA2-X potently reduced gene transfer of HIV-1 Env-pseu
287                                We found that sPLA2-X protein is increased in the airways of patients
288                                          The sPLA2-X protein is located in the endoplasmic reticulum,
289                                          The sPLA2-X protein is regulated by proteolytic cleavage, su
290  sPLA2-X and indirect AHR in asthma and that sPLA2-X serves as an epithelial regulator of inflammator
291 ombinant sPLA2-X and show that low levels of sPLA2-X stimulate both tyrosinase activity and melanocyt
292 e used confocal microscopy to colocalize the sPLA2-X to intracellular structures.
293  sPLA2-X, to investigate the contribution of sPLA2-X to the measure of sPLA2 activity and coronary he
294 n humans, and the regulation and function of sPLA2-X within the epithelium.
295           Secretory phospholipase-A2 type X (sPLA2-X) is released by epidermal keratinocytes and we h
296           Secreted phospholipase A2 group X (sPLA2-X) plays a key role in regulating eicosanoid forma
297                   A specific secretory PLA2, sPLA2-X, is shown here to neutralize human immunodeficie
298 dy and complement were sensitive to lysis by sPLA2-X, suggesting a novel mechanism of antiviral surve
299 to use genetic variants of PLA2G10, encoding sPLA2-X, to investigate the contribution of sPLA2-X to t
300 LA2-IVA, cPLA2-IVB, iPLA2-VI, sPLA2-IIE, and sPLA2-XIIA.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top